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Abstract
Background
Invasive pneumococcal disease (IPD) is a major cause of illness and death among children
worldwide. 10-valent pneumococcal conjugate vaccine (PCV10) was introduced as part of
the Mozambican routine immunization program in April 2013. We characterized the IPD bur-
den in a rural area of Mozambique before PCV introduction and estimated the potential
impact of this intervention.
Methods
We conducted population-based surveillance for IPD, defined as S. pneumoniae isolated
from blood or cerebrospinal fluid, among children <5 years old admitted to Manhic¸a District
Hospital, a referral hospital in a rural area with high prevalence of human immunodiciency
virus infection. S. pneumoniae was identified using standard microbiologic methods and ser-
otyped using sequential multiplex PCR or Quellung. IPD incidence was calculated among
cases from a defined catchment area.
Results
From January 2001 through December 2012, we isolated 768 cases of IPD, 498 (65%) of
which were bacteraemic pneumonia episodes. A total of 391 (51%) were from the catch-
ment area, yielding IPD incidence rates of 479, 390 and 107 episodes per 100,000 children-
years at risk among children <12, 12–23 and 24-<60 months old, respectively. The overall
IPD incidence fluctuated and showed a downward trend over time. In these same age
groups, in-hospital death occurred in 48 (17%), 26 (12%), and 21 (13%) of all IPD cases,
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respectively. Overall 90% (543/603) of IPD isolates were available for serotyping; of those,
65% were covered by PCV10 and 83% by PCV13. Among 77 hospital deaths associated
with serotyped IPD, 49% and 69% were caused by isolates included in the PCV10 and
PCV13, respectively.
Conclusions
We describe very high rates of IPD among children in rural Mozambique that were declining
before PCV introduction. Children <1 year old have the greatest incidence and case fatality;
although the rates remain high among older groups as well. Most IPD episodes and many
deaths among children <5 years old will likely be prevented through PCV10 introduction in
Mozambique.
Introduction
Streptococcus pneumoniae is a leading cause of bacterial pneumonia, bacteremia/sepsis, and
acute meningitis in children worldwide [1]. The World Health Organization (WHO) esti-
mated that approximately 541,000 children less than 5 years old died in 2008 of pneumococcal
disease [2], and most pediatric pneumococcal deaths occur in developing countries [1]. In
2007, based on demonstrated efficacy and safety of a 7-valent and a 9-valent pneumococcal
conjugate vaccine (PCV) [3–6], WHO recommended that PCV be included in routine immu-
nization programs, especially in countries with high mortality rates among children under the
age of 5 years and high prevalence of HIV infection [7]. In 2009 and 2010, 10-valent (PCV10)
and 13-valent (PCV13) PCVs were licensed, offering improved coverage for prevalent pneu-
mococcal serotypes, particularly in Africa where serotypes 1 and 5 are frequent [8]. PCVs have
been increasingly introduced in sub-Saharan Africa in recent years [9]. However, due to diffi-
culties in building the necessary laboratory and epidemiologic capacities, few African settings
have high-quality population-based surveillance for invasive pneumococcal disease.
Since 2001, the Centro de Investigação em Saúde de Manhiça (CISM) has been conducting
surveillance for invasive bacterial disease among children in rural Mozambique [10–12]. Data
from this surveillance system were instrumental in prompting the Mozambican Ministry of
Health to apply for GAVI Alliance support to introduce Hib conjugate vaccine in August,
2009 and PCV10 in April, 2013. PCV10 was introduced using a 3-dose schedule (given at 2, 3,
and 4 months of age) with no catch-up campaign. We examined pre-PCV surveillance data in
order to describe the burden of invasive pneumococcal disease (IPD) before vaccine introduc-
tion and to estimate the anticipated impact of PCV introduction on pneumococcal illness and
death among children in Mozambique.
Material and methods
Study area and population
Surveillance for invasive pneumococcal disease (IPD) is routinely conducted at Manhic¸a Dis-
trict Hospital (MDH), a referral district hospital in Southern Mozambique. Details of the study
site have been described elsewhere [13]. Manhic¸a district has a total population of approxi-
mately 165,000 persons, 18% of which are children <5 years old [14]. The area is rural,
malaria-endemic [15] and with a high burden of human immunodeficiency virus (HIV); HIV
prevalence among pregnant woman was estimated to be 24% in 2003 to 2005 [16] and overall
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community prevalence peaked at 39% in 2011 [17]. Within the district, CISM has maintained
a continuous demographic surveillance system (DSS) since 1996, recording life events (preg-
nancy, births, deaths and migration in or out of the study area) and performing updates bian-
nually from 1996 to 2012. The DSS area initially included approximately 36,000 people; by
2005 it had been expanded to include 92,000 people; which correspond to 58% of the total dis-
trict population in Manhic¸a [13].
The protocol for population-based invasive pneumococcal surveillance described in this
study was reviewed and approved by the Mozambican National Bioethics Committee, the
Institutional Review Board of the Clinic Hospital of Barcelona (Barcelona, Spain), and was
determined to be non-human subjects research by the U.S. Centers for Disease Control and
Prevention.
Morbidity surveillance and sample collection
Since January 1997, CISM has operated pediatric morbidity surveillance at MDH and
within a network of 5 peripheral health centers within the DSS area [10, 12]. In these health
facilities, trained clinical personnel perform physical examinations and complete standard-
ized forms to record demographic information, presenting signs and symptoms, and clini-
cal outcomes. During the study period, HIV testing results were not routinely available;
because of concern about stigma. HIV testing was often performed anonymously and there-
fore the results are not linkable to the IPD surveillance database. At MDH, the only site with
admission facilities and linked to demographic surveillance, 1–3 mL of blood for culture are
obtained by venipuncture upon admission and before administration of antimicrobials for
all children <2 years requiring hospitalization and for those 2-<15 years with axillary tem-
perature 39˚C or other signs of severe disease. Lumbar puncture to collect cerebrospinal
fluid (CSF) is systematically performed on all children with suspected meningitis and
admitted infants <29 days old.
Bacteriological procedures
Pediatric blood culture bottles (Pedibact1, Becton-Dickinson, Franklin Lakes, NJ) were inoc-
ulated with 1–3 ml of whole blood and incubated in an automated system (BACTEC1 9050
Becton-Dickinson, Franklin Lakes, NJ) for 4 days. Post-incubation specimens from blood cul-
ture bottles with a Gram stain compatible with pneumococcus were sub-cultured onto blood
agar and incubated overnight at 37˚C in 5% CO2. CSF samples were first stained by Gram and
subsequently cultured onto blood agar, chocolate blood agar and thioglycolate broth media for
72h, at 37˚C in an atmosphere of 5% CO2. Thioglycolate broths were subcultured on chocolate
blood agar media and incubated for 72h. Pneumococci were identified by α-hemolysis and
typical colony morphology and confirmed by optochin sensitivity.
Serotyping of pneumococcal isolates was consistently performed starting in 2003. Pneumo-
coccal strains were initially serotyped at the CDC Streptococcus laboratory by Quellung reac-
tion with serotype-specific antiserum [18]. Since 2006, serotyping has been performed at
CISM using sequential multiplex PCR [19], with quality control and resolution of serogroups
that cannot be differentiated by PCR done at CDC in Atlanta by Quellung method.
All pneumococcal isolates from 2008 to 2010 were tested for antibiotic susceptibility using
broth microdilution method. Isolates were classified as susceptible, intermediate or resistant
according to the definitions of the National Committee for Clinical and Laboratory Standards
Institute (CLSI) for bacteremia [20] for 2011.
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Definitions
A case of IPD was defined as the isolation of S. pneumoniae from a normally sterile site (such
as blood or CSF) in a child<5 years of age presenting to MDH. Cases with S. pneumoniae
detected in CSF (CSF only or in both CSF and blood) were classified as pneumococcal menin-
gitis; all other cases with S. pneumoniae in the blood were classified as bacteraemia. Among
bacteraemia cases, those with cough and/or breathing difficulties plus tachypnea were classi-
fied as bacteraemic pneumonia. Case-fatality for IPD episodes excludes patients with unknown
outcome; 90 children out of 670 (because were referred to referral hospital or absconded from
the hospital), and thus represents in-hospital mortality. PCV10 serotypes include 1, 4, 5, 6B,
7F, 9V, 14, 18C, 19F and 23F; because of potential cross-protection against serotype 6A [21],
we also examined PCV10 serotypes plus 6A. PCV13 includes the same pneumococcal sero-
types included in the PCV10 plus 3, 6A and 19A.Weight-for-age z-score was calculated using
WHO child growth chart standards [22].
Data management and analysis
Data from standardized forms were double entered using visual Fox Pro version 2.6 (Microsoft
Corporation, Redmond, WA) at CISM. Proportions were compared using the X2 test. We cal-
culated the incidence rates of IPD, pneumococcal bacteremia and pneumococcal meningitis
among children <1 year, 1–2 years, 2-<5 years from the DSS area. Recurrent detection of S.
pneumoniae within 14 days of the first positive culture was considered the same episode of
IPD. To estimate incidence, person-time of follow-up for children in the demographic surveil-
lance area was calculated per 100,000 children-years at risk (CYR) using dates of birth and
death, excluding periods of outmigration. Negative binomial regression models were devel-
oped to estimate incidence rates overall and by age-group. Models were estimated with ran-
dom intercept to take into account repeated measures, since children can belong to several age
categories or to several calendar years during the surveillance period.
Statistical analyses were performed using STATA software (version 12.0, STATA Corpora-
tion, College Station, TX).
Results
From 1st January 2001 to 31st December 2012, there were 41,106 admissions to MDH among
children <5 years of age, of which 48% were from the DSS catchment area. Per hospital proto-
col, blood culture was indicated for nearly all admitted children (n = 41,032, 99.8%); and it was
performed for 34,947 (85%) of admissions with an indication. CSF culture was done for 3,347
patients, representing 8% of all admissions and 56% (3,347/6,006) of those with an indication
for lumbar puncture per hospital protocol. The proportion of eligible patients undergoing
lumbar puncture was lowest during the first two years of surveillance (569/1,264, 45%); in
more recent years the proportion ranged from 82% to 85%.
A total of 768 IPD cases were identified, including 498 (65%) bacteraemic pneumonia epi-
sodes, 218 (28%) bacteraemia (non-pneumonia) cases and 52 (7%) pneumococcal meningitis
cases (Table 1). Among pneumococcal meningitis cases, 35 (67%) had S. pneumoniae isolated
from blood in addition to being detected in the CSF. Overall, 55% (425/768) of IPD cases were
in males and 76% (584/768) occurred among children under the age of<24 months. Among
64 cases (8%) with documented HIV status, 34 (53%) occurred in HIV-infected children.
Among 667 cases with known nutritional status, 159 (24%) had severe malnutrition. Hospital
death occurred in 48 (17%), 26 (12%), and 21 (13%) of all cases aged<12 months, 12–23
months and 24-<60 months old respectively (p = 0.078). Overall case fatality was 14% (95/
670), and significantly higher among pneumococcal meningitis cases (38%; 15/40) compared
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with non-meningitis syndromes (13%, 80/630; p = 0.001), among cases with known outcomes.
Almost half (51%; 48/95) of IPD death occurred among infants.
Incidence rate: Among 391 IPD cases from the DSS area, 4 were in children who had a pos-
itive pneumococcal culture within the prior 15 days; thus a total of 387 unique IPD episodes
were detected. The overall incidence was 245 episodes per 100,000 CYR (Table 2). Rates were
highest among infants 0–11 months (479 episodes per 100,000 CYR) and among children aged
12–23 months (390 episodes per 100,000 CYR). Incidence rates for all children <5 years varied
Table 1. Characteristics of IPD cases (n = 768) detected from January 2001 to December 2012 at Manhic¸a District Hospital, in Mozambique.
Characteristics Bacteraemic pneumonia Bacteraemia (non-Pneumonia) Meningitis Overall
n = 498 n = 218 n = 52 N = 768
n (%) n (%) n (%) n (%)
Gender: male 269 (54) 127 (58) 29 (56) 425 (55)
Age (months)
Median (interquartile range) 14 (8 to 24) 11 (7 to 20) 8.5 (4 to 18) 13 (7 to 23)
0–11 195 (39) 111 (51) 30 (58) 336 (44)
12–23 174 (35) 62 (28) 12 (23) 248 (32)
24-<60 129 (26) 45 (21) 10 (19) 184 (24)
Malnutrition* 135 (30) 48 (27) 22 (45) 22 (45)
None 135 (30) 48 (27) 22 (45) 22 (45)
Mild 86 (20) 51 (28) 13 (27) 150 (23)
Moderate 104 (24) 38 (21) 11 (22) 153 (23)
Severe 112 (26) 44 (24) 3 (6) 159 (24)
Seasonality
Rainy season (October–March) 234 (47) 96 (44) 26 (50) 356 (46)
Hospitalized duration (days)
Median (interquartile range) 6 (3 to 9) 5 (3 to 8) 3 (2 to 5) 5 (3 to 9)
Case fatality by age group**
0–11 months 24/169 (14) 12/97(12) 12/24(50) 48/290 (17)
12–23 months 18/151 (12) 6/52 (12) 2/9 (22) 26/212 (12)
24-<60 months 17/119 (14) 3/42 (7) 1/7 (14) 21/168 (13)
Overall 59/439 (14) 21/191 (11) 15/40 (38) 95/670 (14)
*Among for 667 IPD cases with complete weight or age data for weight for age Z-score (waz) calculation (waz >-2 to <-1 Mild; waz>-3 to <-2 Moderate;
waz<-3 severe).
** Among 670 IPD cases with known outcome (missing date in 47 among infants (<12 months), 36 among children age 12-<24m and 16 among children
age 24-<60).
https://doi.org/10.1371/journal.pone.0190687.t001
Table 2. Incidence rate of IPD among children <5 years old in rural Mozambique per different age groups, in Manhic¸a District Hospital.
Age groups (months) Episodes Time at risk Incidence IRR# 95%
(CYR) (Episodes per 100,000 CYR*) Conf. Interval
0–11 163 34,018 479 1
12–23 126 32,345 390 0.82 (0.65–1.04)
24–59 98 91,848 107 0.23 (0.17–0.29)
TOTAL 387 158,211 245 - -
* CAR = children-years at risk.
# IRR = Incidence Rate Ratio.
https://doi.org/10.1371/journal.pone.0190687.t002
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over time, with a peak incidence of 531 episodes per 100,000 CYR in 2002–2003 (Fig 1). Over-
all, during the study period there was a trend toward declining incidence rates, with the lowest
rate observed in 2012 (106 episodes per 100,000 CYR).
Serotypes: From 603 IPD episodes occurring in 2003–2012, 543 (90%) isolates were avail-
able for serotyping. Among those, 5 (1%) were non-typable. Among the remaining 538, 37 dif-
ferent serotypes were detected. The most prevalent serotypes were 6A (13.9%), 1 (13.2%), 14
(11.2%), 5 (10.7%), 6B (9.0%), and 23F (6.1%), (Fig 2). Three (<1%) isolates were classified as
6AB by PCR but no isolate was available to definitively determine serotype by Quellung. The
relative contribution of different serotypes varied over time, with the greatest number of sero-
types 1, 14 and 23F cases observed in 2003 and in 2009 the greatest number it was recorded for
serotypes 5, 6A and 14 (Fig 3).
The proportion of cases due to serotypes included in PCV10 and PCV13 were 65% and
83%, respectively, with the difference attributable primarily to serotypes 6A and 19A. If we
assume cross protection against 6A from PCV10, then the proportion of cases covered by
Fig 1. Annual incidence rates of IPD cases among children <5 years of age admitted at Manhic¸a
District Hospital, in Mozambique between 2001–2012.
https://doi.org/10.1371/journal.pone.0190687.g001
Fig 2. Serotypes distribution of pneumococcal isolates (n = 546) in blood and CSF of children <5
years of age admitted at Manhic¸a District Hospital, in Mozambique: 2003–2012.
https://doi.org/10.1371/journal.pone.0190687.g002
The burden of invasive pneumococcal disease in Mozambique
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PCV10 increases to 78%. Serotype coverage did not vary significantly by clinical syndrome,
age group or by year (Table 3). Serotype data were available for 77 IPD in-hospital deaths; 38
(49%) were due to serotypes included in PCV10 and 52 (69%) due to serotypes included in
PCV13.
Fig 3. Number of IPD cases caused by most common vaccine types among children <5 years of age admitted at Manhica District Hospital, 2003–
2012.
https://doi.org/10.1371/journal.pone.0190687.g003
Table 3. Proportion of pneumococcal disease syndromes potentially preventable by PCV formula-
tion, among children < 5 years of age in Mozambique.
PCV10 PCV13
n/N % n/N %
Overall 383/588 65 488/588 83
Clinical syndromes
Bacteraemic pneumonia 247/375 66 310/375 83
Bacteraemia (non-pneumonia) 105/165 64 141/165 85
Pneumococcal Meningitis 31/48 65 37/48 77
Age group
0–11 months 166/263 63 210/263 80
12–23 months 118/187 63 159/187 85
24–59 months 99/138 72 119/138 86
https://doi.org/10.1371/journal.pone.0190687.t003
The burden of invasive pneumococcal disease in Mozambique
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Antimicrobial susceptibility: Table 4 summarizes pneumococcal antimicrobial resistance
of 195 IPD isolates between 2008 and 2010. Resistance to cotrimoxazole was most common
(54.4%), followed by tetracycline (23.6%) and chloramphenicol (14.4%). Resistance to beta lac-
tam antibiotics was low, with<1% resistant to penicillin or ampicillin. Among 106 isolates
resistant to cotrimoxizale, 68 (64%) were vaccine serotypes.
Discussion
We demonstrate an extremely high, yet dynamic, burden of paediatric pneumococcal disease
in rural Mozambique before PCV introduction. The overall incidence observed during the
twelve year period examined was 245 cases of IPD per 100,000 CYR among children <5 years
old, which is higher than what has been reported for this age group from other African sites.
Consistent with studies from other locations [23–27], the greatest burden was observed among
infants <12 months (479 per 100,000 CYR), followed by 12–23 month olds (390 per 100,000
CYR). Even these very high incidences, however, are likely an underestimate, since more than
50% of paediatric deaths in the study area occur at home with no previous hospital attendance
[28]. With a case fatality proportion of 14% overall and 29% among meningitis cases, our find-
ings highlight the importance of S. pneumoniae as a cause of death among young children and
the need to prevent pneumococcal deaths in order to achieve Millennium Development Goal
4.
PCV10 was introduced in the routine infant immunization program in Mozambique in
April, 2013. Extrapolating the observed incidence rates in 2012 to 4,332,000 Mozambican chil-
dren <5 years of age in 2012 [14], we estimate 4,592 hospitalizations for IPD and 643 IPD in-
hospital deaths among children <5 years olds nationwide occur each year. Assuming 65% of
these IPD cases and 49% of the deaths could be prevented by PCV10, approximately 2,985
admissions and 315 deaths could be averted annually. Available data on PCV10 impact [29]
and effectiveness [30] from other countries suggest that it is highly protective against vaccine-
type IPD among young children; however, these studies have been conducted in places with
relatively low HIV prevalence. Data on PCV effectiveness against IPD among HIV-infected
children are limited and inconclusive [5, 31]. Continued surveillance for IPD in Mozambique,
an area with a very high burden of both HIV and pneumococcal disease, will provide impor-
tant data on the benefits of PCV10 introduction in populations with a high-HIV prevalence.
Table 4. Antibmicrobial susceptibility for 195 invasive pneumococcal isolates with antimicrobila susecptability performed from children <5 years
old, hospitalized at Manhic¸a District Hospital, Mozambique.
Antibiotics Intermediate* Resistant* Range MICs
n (%) n (%)
Erythromycin 0 7 (3.6) 0.03 to >32
Penicillin # 0 1 (0.5) 0.03 to 4
Amoxicillin 0 1 (0.5) 0.03 to 4
Cefotaxime 0 0 0.06 to 1
Clindamycin 0 3 (1.5) 0.03 to >2
Cotrimoxazole 57 (29.2) 106 (54.4) 0.12 to >4
Chloramphenicol - 28 (14.4) 2 to >8
Tetracycline 0 46 (23.6) 2 to >8
# Using CLSI 2011 breakpoints 4ug/ml for intermediate and8ug/ml for resistant for non-meningitis isolates.
*The percentage indicates the pneumococcal isolates resistant or intermediate among the 195 invasive pneumococcal isolates tested for antibiotic
susceptibility
https://doi.org/10.1371/journal.pone.0190687.t004
The burden of invasive pneumococcal disease in Mozambique
PLOS ONE | https://doi.org/10.1371/journal.pone.0190687 January 5, 2018 8 / 13
Based on the serotype results, PCV13 would offer protection against a higher proportion of
IPD cases in Mozambique (83% versus 65% coverage for PCV10 and 78% coverage for PCV10
+6A). Since the two serotypes that primarily account for the difference were 6A and 19A, the
true difference between the coverage of the two formulations may depend upon cross-protec-
tion from vaccine serotypes (6B and 19F). PCV7, which included serotype 6B, was shown in a
case-control study to be 76% (95% CI 39, 90) effective against IPD caused by serotype 6A [32]
and rates of 6A IPD fell in variety of settings where PCV7 was introduced [33, 34]. Immunoge-
nicity studies suggest that PCV10 should also provide cross-protection against serotype 6A
[35, 36]. A case-control study in Brazil did not find significant PCV10 effectiveness against
serotype 6A IPD, although power was limited [30]. That study did show an effectiveness of
82.2% (95% CI 10.7–96.4) against serotype 19A. However pneumococcal carriage data from
Kenya show no impact of PCV10 introduction on carriage with serotype 6A or 19A [37]. The
uncertainty about PCV10 cross protection underscores the need to monitor trends in non-vac-
cine serotypes following PCV10 introduction in Mozambique.
Our data also highlight the challenges in evaluating PCV10 impact due to the dynamic
nature of pneumococcal disease. The incidence initially increased from 2001 to 2002, followed
by a general downward trend over the course of the study period, albeit with year-to-year vari-
ation and relative increases observed in 2006 and 2011. The annual incidence ranged consider-
ably from year to year, with a 5-fold difference between the lowest (106 per 100,000 CYR in
2012) and highest (531 per 100,000 CYR in 2002) annual rates measured. Certain pneumococ-
cal serotypes (such as serotypes 1 and 5) can fluctuate over time, dramatically altering IPD
trends. From 2003 on serotype 1 disease declined steadily, which may represent the resolution
of a serotype 1 outbreak. The increase in overall IPD seen from 2001 to 2002 (before serotyping
was routinely performed) is difficult to explain, but could also represent fluctuations in sero-
type 1. The general decline in IPD incidence over the course of the study period may have
been influenced by a variety of factors including HIV prevalence and clinical management,
socioeconomic and nutritional status. Improved access to antiretroviral treatment for HIV has
been associated with a decline in IPD burden among HIV-infected children in South Africa
[38] and HIV-infected adults in Malawi [39, 40]. Attempts to assess PCV10 impact by studying
IPD trends over time must take into account pre-vaccine trends, and may be complemented
by other methods (such as case-control vaccine effectiveness studies) or trends in other out-
comes (i.e. pneumonia, pneumococcal carriage).
Antibiotic resistance data derived from this study are reassuring. Despite a high prevalence
of penicillin resistance among pneumococcal isolates from other settings [41–43] we found
less than 1% of strains to be resistant to beta-lactam antibiotics. These data support the empiri-
cal use of penicillin for management of pediatric pneumonia and suspected bacteremia/sepsis.
Several factors should be considered when interpreting these data. Only a single blood cul-
ture specimen was collected for each patient and lumbar punctures were performed for less
than half of the children with suspect meningitis. Children with severe illness may die at home
due to distance to health facilities and other barriers to care. HIV testing results were not avail-
able for the most IPD cases during this pre-PCV period and estimates of HIV prevalence in
pediatric population are not available. The lack of data on HIV status make it impossible to cal-
culate HIV-specific IPD incidence rates, and severely limits our understanding of driving
forces behind the pre-PCV decline in IPD. Therefore these incidence estimates represent a
minimum burden of disease. Nonetheless we report a remarkably high burden of invasive
pneumococcal illness and death in this rural African setting with a high prevalence of HIV and
limited access for antiretroviral treatment among children HIV-infected. Our findings suggest
that recently introduced PCV10 will have a major impact on hospitalizations, death and health
The burden of invasive pneumococcal disease in Mozambique
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care costs in Mozambique. Efforts to measure that impact must take into account the complex
nature of IPD and pre-vaccine trends in disease.
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